Blood Pressure and Brain Blood Flow Regulation After Midodrine Administration in Those With Spinal Cord Injury

Brief Title

Blood Pressure and Brain Blood Flow Regulation After Midodrine Administration in Those With Spinal Cord Injury

Official Title

Neural and Mechanical Baroreflex Sensitivity and Cerebral Blood Flow

Brief Summary

      This project aims to evaluate the physiological effects of Midodrine administration during
      orthostatic challenge in those with high level spinal cord injury. Midodrine has been shown
      to improve orthostatic symptoms in those with spinal cord injury but the physiological
      mechanisms influenced have not been identified. The investigators will examine key
      physiological components influencing orthostatic tolerance. The investigators will do this,
      by measuring the baroreflex, and brain blood flow autoregulation (the ability to maintain
      brain blood flow) before during and after the sit-up test. Two sit-up tests will occur; one
      before Midodrine administration, and one after administration of a 10mg dose of Midodrine.
    



Study Type

Observational


Primary Outcome

Baroreflex sensitivity

Secondary Outcome

 Cerebral autoregulation

Condition

Orthostatic Intolerance

Intervention

Midodrine


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

22

Start Date

March 2012

Completion Date

November 2013

Primary Completion Date

November 2013

Eligibility Criteria

        Inclusion Criteria:

          -  To be included in the study, participants must have sustained a traumatic spinal cord
             injury within the ages of 18-49 years.

          -  Also, participants must have an injury level above the 6th thoracic vertebrae and be a
             non-smoker for a minimum of one year.

        Exclusion Criteria:

          -  Any participants with a history of cardiovascular disease, pulmonary disease or
             diabetes mellitus will not be eligible.

          -  Also, participants will not be eligible to take part in study if they experiences
             acute distress, or are taking medications known to influence cardiovascular function.

          -  Patient will be not eligible for the study if he/she has known adverse reaction to
             Midodrine.
      

Gender

All

Ages

18 Years - 49 Years

Accepts Healthy Volunteers

No

Contacts

Darren Warburton, PhD, , 

Location Countries

Canada

Location Countries

Canada

Administrative Informations


NCT ID

NCT01498809

Organization ID

H11-02823


Responsible Party

Principal Investigator

Study Sponsor

University of British Columbia


Study Sponsor

Darren Warburton, PhD, Principal Investigator, University of British Columbia


Verification Date

September 2019